Mesenchymal stem cells in transplantation and tissue regeneration

Martin J Hoogduijn ,Frank J M F Dor

doi:10.3389/fimmu.2011.00084

Abstract

Mesenchymal stem cells in transplantation and tissue regeneration

Highlights

The characteristics of Mesenchymal stem cells (MSC) initiated interest in their potential clinical use for tissue regenerative and immunomodulatory purposes
The use of MSC for the treatment of a variety of diseases has been investigated in clinical trials, including in Crohn’s disease (Duijvestein et al, 2010), myocardial infarction (Hare et al, 2009), rheumatoid arthritis (Liang et al, 2011), multiple sclerosis (Freedman et al, 2010), and organ transplantation (Dahlke et al, 2009)
There is evidence that MSC therapy has a tissue regenerative component that repairs organ injury caused by immunological or ischemic events and thereby prevents the loss of organ transplants in animal models (Morigi et al, 2008; Popp et al, 2008). This may offer another window of opportunity for MSC therapy in particular shortly after transplantation, when organ loss peaks partly due to ischemia–reperfusion injury of the graft

Summary

Introduction

The characteristics of MSC initiated interest in their potential clinical use for tissue regenerative and immunomodulatory purposes. The use of MSC for the treatment of a variety of diseases has been investigated in clinical trials, including in Crohn’s disease (Duijvestein et al, 2010), myocardial infarction (Hare et al, 2009), rheumatoid arthritis (Liang et al, 2011), multiple sclerosis (Freedman et al, 2010), and organ transplantation (Dahlke et al, 2009). The use of MSC is aimed at the prolongation of allograft survival.

Results

Conclusion